肝細胞癌に対するミリプラチン・シスプラチン併用（ダブルプラチナ）懸濁液による肝動脈化学塞栓療法の安全性と効果の初期検討
スポンサーリンク
概要
- 論文の詳細を見る
Purpose: To evaluate local control effects of transcatheter arterial chemoembolization (TACE) using miriplatin and cisplatin (double platinum-lipiodol suspension TACE: [DP-TACE]), and its safety for inoperable hepatocellular carcinoma (HCC). Materials and methods: Between March 2010 and March 2011, 91 HCC cases were treated with superselective DP-TACE. The treatment effect (TE) was determined after 2-3 months of therapy. Adverse events were evaluated using Common Terminology Criteria for Adverse Events v4.0. Results: 37 (40.6%) HCCs showed TE4; 22 (24.2%), TE3; 22 (24.2%), TE2; 10 (11.0%), TE1. Fifty-one HCCs < 30 mm in diameter were TE3+4 and 8 HCCs ≥ 30 mm were TE3+4 (p<0.001). Adverse events were limited to grade 1, 2 or 3 and all cases were transient. Conclusion: The antitumor efficacy of DP-TACE was acceptable.
- 一般社団法人 日本肝臓学会の論文
一般社団法人 日本肝臓学会 | 論文
- 肝癌に対するバイポーラ電極針を用いたラジオ波熱凝固療法～当院における初期使用経験～
- 座談会 C型肝炎の抗ウイルス療法：日本肝臓学会の治療ガイドラインをめぐって
- 良性肝細胞性結節の病理診断：新WHO分類をふまえて
- 妊娠中に発症し胎児に腹水を認めた自己免疫性肝炎の1例
- 同一肝亜区域内に混合型肝癌と肝細胞癌が存在した重複癌の1例―First case―